非酒精性脂肪性肝病的诊疗进展

摘要/Abstract

摘要： 近年来,随着肥胖、糖尿病等代谢性疾病发病率的逐年增高,非酒精性脂肪性肝病的发病率也迅速上升,并且由于其发病机制复杂、诊断困难、缺乏理想的药物以及标准的治疗方法,非酒精性脂肪性肝病已成为人类健康问题中所面临的一项巨大挑战,未来或许会成为慢性肝病的主要形式。本文综述了近年来有关非酒精性脂肪性肝病发病的危险因素、诊断和治疗的研究,总结并分析了其可能的发病机制,以期为以后的研究提供理论依据。

关键词: 非酒精性脂肪性肝病, 危险因素, 发病机制, 诊断, 治疗

Abstract: As the incidence of obesity, diabetes and so on in recent years gradually increased, the incidence of nonalcoholic fatty liver disease rapidly rising. And due to the complexity of its pathogenesis diagnosis difficult Lack of ideal drug and standard treatment, nonalcoholic fatty liver disease has become a major challenge in human health problems, the future may become the main form of chronic liver disease. This article reviews the recent studies on the risk factors, diagnosis and treatment of non-alcoholic fatty liver disease, and summarizes and analyzes its possible pathogenesis, in order to provide theoretical basis for future studies and improve the cure rate of the disease.

Key words: NAFLD, Risk factor, Pathogenesis, Diagnosis, treatment

中图分类号:

杨芳丽, 王昕. 非酒精性脂肪性肝病的诊疗进展[J]. 中华养生保健, 2023, 41(7): 49-53.

YANG Fang-li, WANG Xin. Progress in the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(7): 49-53.

参考文献

[1] POUWELS S, SAKRAN N, GRAHAM Y, et al.Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocrine Disorders,2022,22(1):63.
[2] 郑娜,戴孟.膈下逐瘀汤合二陈汤加减治疗非酒精性脂肪性肝炎临床研究[J].新中医,2018,50(11):98-101.
[3] AHMED M.Non-alcoholic fatty liver disease in 2015[J]. World journal of hepatology,2015,7(11):1450-1459.
[4] PAPATHEODORIDI M, CHOLONGITAS E.Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts[J]. Current pharmaceutical design,2018,24(38):4574-4586.
[5] CUSI K, ISAACS S, BARB D, et al.American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. Endocrine Practice,2022,28(5):528-562.
[6] NORBERT S, HANS-ULRICH H, KENNETH C.Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. The Lancet Diabetes & Endocrinology,2019,7(4):313-324.
[7] CHALASANI N, YOUNOSSI Z, LAVINE J E, et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2018,67(1):328-357.
[8] Younossi Z, Tacke F, Arrese M, et al.Global perspectives on nonal-coholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatol-ogy,2019,69(6):2672-2682.
[9] ESLAM M, SANYAL A J, GEORGE J, et al.MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology Gastroenterology,2020,158(7):1999-2014.
[10] 刘妍君. 西北燥证与NAFLD合并糖脂代谢异常的相关性分析[D].乌鲁木齐:新疆医科大学,2018.
[11] BYRNE C D, TARGHER G.NAFLD: a multisystem disease[J]. J Hepatol,2015,62(1 Suppl):S47-S64.
[12] LUUKKONEN P K, QADRI S, AHLHOLM N, et al.Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol,2022,76(3):526-535.
[13] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
[14] 周颖,方林花,林敏.非酒精性脂肪肝并发肝功能损害的危险因素分析[J].全科医学临床与教育,2020,18(10):900-903.
[15] 高黎明,孙宏文.非酒精性脂肪性肝病与代谢综合征及影响因素相关性研究进展[J].胃肠病学和肝病学杂志,2020,29(7):829-833.
[16] HENRY L, PAIK J, YOUNOSSI Z M.Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world[J]. Aliment Pharmacol Ther,2022,56(6):942-956.
[17] DAI W, YE L, LIU A, et al.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis[J].Medicine (Baltimore),2017,96(39):e8179.
[18] YOUNOSSI Z M, TAMPI R P, RACILA A, et al.Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S[J]. Diabetes Care,2020,43(2):283-289.
[19] SHIN H S, JUN B G, YI S W.Impact of diabetes, obesity, and dyslipidemia on the risk of HCC in patients with chronic liver diseases[J]. Clin Mol Hepatol,2022,28(4):773-789.
[20] WU K T, KUO P L, SU S B, et al.Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol[J]. J Clin Lipidol,2016,10(2):420-425.
[21] 李洋洋,谢正元.非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J].临床肝胆病杂志,2021,37(2):452-457.
[22] 王玉丽,胡莹莹,王晔,等.MR定量分析非酒精性脂肪性肝病患者肝脂肪含量与代谢综合征的相关性[J].中国医学影像技术,2020,36(12):1853-1857.
[23] LORBEER R, BAYERL C, AUWETER S, et al.Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease[J]. J Hypertens,2017,35(4):737-744.
[24] ZHANG T, ZHANG C, ZHANG Y, et al.Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population:a prospective cohort study[J]. Atherosclerosis,2015,240(1):144-148.
[25] BUZZETTI E, PINZANI M, TSOCHATZIS E A.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism,2016,65(8):1038-1048.
[26] ANTY R, GUAL P.Physiopathologie des stéatoses hépatiques métaboliques[Pathogenesis of non-alcoholic fatty liver disease][J]. Presse Med,2019,48(12):1468-1483.
[27] 孙丹莉,张予蜀,张振玉,等.紧密连接蛋白Occludin在非酒精性脂肪肝大鼠肠上皮细胞中的表达及其与TNF-α的关系[J].世界华人消化杂志,2010,18(10):981-986.
[28] KIRPICH I A, MARSANO L S, MCCLAIN C J.Gut-liver axis,nutrition,and non-alcoholic fatty liver disease[J]. Clin Biochem,2015,48(13-14):923-930.
[29] ARAB J P, KARPEN S J, DAWSON P A, et al.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
[30] COBBINA E, AKHLAGHI F.Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification,and effect on drug metabolizing enzymes and transporters[J]. Drug Metab,2017,49(2):197-211.
[31] 林雪梅,陈珊,唐玉琴,等.清肝健脾法治疗脾虚痰瘀互结型非酒精性脂肪性肝炎40例临床观察[J].中国民间疗法,2020,28(21):67-71.
[32] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息,2018,31(5): 393-402,420.
[33] 周滔,张声生,郁强.调肝理脾法治疗非酒精性脂肪肝的临床队列研究[J].北京中医药,2013,32(6):403-405.
[34] 杨杰,曹玉芝,徐永升,等.373例非酒精性脂肪性肝病FibroTouch检测临床观察[J].中国实用医药,2017,12(24):33-34.
[35] MAKRI E, GOULAS A, POLYZOS S A. Epidemiology,Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease[J]. Arch Med Res,2021,52(1):25-37.
[36] NEWSOME P N, SASSO M, DEEKS J J, et al.FibroScan-AST (FAST) score for the non-invasive identification of patients with nonalcoholic steatohepatitis with significant activity and fibrosis:a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol,2020,5(4):362-373.
[37] 张姝嫔,程成,祝怡婕,等.超声衰减成像定量诊断非酒精性脂肪肝的应用价值初探讨[J].中国超声医学杂志,2021,37(1):66-69.
[38] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) andEuropean Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.
[39] POLYZOS S A, KOUNTOURAS J, PAPATHEODOROU A, et al.Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index[J]. Ann Hepatol,2013,12(5):749-757.
[40] POYNARD T, RATZIU V, CHARLOTTE F, et al.Diagnostic value of biochemical markers (Nash Test) for the prediction of non alcoholo steatohepatitis in patients with non-alcoholic fatty liver disease[J]. BMC Gastroenterol,2006,6:34.
[41] CHITTURI S, WONG V W S, CHAN W K, et al. The Asia-Pacific working partyonnon-alcoholicfattyliver disease guidelines 2017-Part2:management and special groups[J]. J Gastroenterol Hepatol,2018,33(1):86-98.
[42] MAURICE J, MANOUSOU P.Non-alcoholic fatty liver disease[J]. Clin Med (Lond),2018,18(3):245-250.
[43] 牙程玉,毛德文,王挺帅,等.非酒精性脂肪性肝病中西医研究进展[J].中西医结合肝病杂志,2021,31(2):188-192.
[44] VENETSANAKI V, KARABOUTA Z, POLYZOS S A.Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis[J]. Eur J Pharmacol,2019,863:172661.
[45] ORCI L A, SANDUZZI-ZAMPARELLI M, CABALLOL B, et al.Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression[J]. Clin Gastroenterol Hepatol,2022,20(2):283-292.